ZHONGSHENGYAOYE(SZ:002317)2025-11-11 10:42Financial Performance - The company achieved a revenue of CNY 1.889 billion from the beginning of 2025 to the end of Q3, remaining stable compared to the previous year [1] - Net profit attributable to shareholders reached CNY 251 million, a year-on-year increase of 68.40% [1] - The net profit excluding non-recurring gains and losses was CNY 246 million, up 30.36% year-on-year [1] - In Q3 alone, the company recorded a revenue of CNY 589 million, an increase of 8.35% year-on-year, with a net profit of CNY 59.03 million, showing a significant growth of 301.03% [1] New Drug Development - The new drug, Angladiwe Tablets, has been successfully approved for market launch, with a comprehensive marketing strategy focusing on academic ecosystem construction, data service upgrades, and key project practices [3] - Angladiwe Tablets is the first oral drug targeting RNA polymerase PB2 for influenza A, demonstrating rapid, effective, and low-resistance characteristics [3] - Clinical trials have shown that Angladiwe Tablets significantly reduce flu symptom relief time compared to placebo, with median relief times of 38.83 hours versus 63.35 hours for adults [6][9] Clinical Trial Results - The Phase II clinical trial for Angladiwe Granules, aimed at children aged 2-17, showed a median flu symptom relief time of 31.72 hours, with high-dose groups achieving 28.63 hours [7] - The safety profile of Angladiwe Granules was favorable, with no serious adverse events reported during the trials [9] - RAY1225 injection, targeting type 2 diabetes and obesity, has shown positive results in Phase II trials, with low rates of gastrointestinal adverse reactions and hypoglycemia [12] Strategic Initiatives - The company is actively seeking international collaborations to expand the market for its innovative drugs, enhancing global R&D capabilities and brand influence [10] - Increased shareholding in its subsidiary, Zhongsheng Ruichuang, aims to strengthen control over innovative drug development and improve operational efficiency [14] - The company is committed to advancing clinical trials for innovative drugs in metabolic and respiratory diseases, focusing on high-quality and accelerated development [12][14]